AI healthtech startup ArcaScience has raised $7 million in seed funding to expand in the US and UK, launch patient solutions, and advance safer drug evaluation.
The round was led by The Moon Venture, with participation from Pléiade Venture, Plug&Play Ventures, Bpifrance, and AKKA. This is ArcaScience’s first institutional funding round and follows a €1.3 million pre-seed raise with Plug & Play Ventures and angel investors.
ArcaScience was founded to tackle a critical weakness in medicine: the lack of tailored treatments and the blind spots in how new drugs are evaluated. After experiencing these inefficiencies firsthand, founder Romain Clement set out to change the system.
The company has since developed AI technology that radically improves benefit-risk assessments for pharmaceuticals, giving regulators, clinical teams, and patients tools to make better, safer decisions.
Romain Clement, Founder and CEO at ArcaScience, explained:
It takes 10+ years to bring a drug to market. There is a 90 per cent fail rate and the average cost per drug that makes it to the market is $2.3 billion. Benefit-risk prediction is no longer a nice-to-have, but a prerequisite for building better drugs. This funding round will help us scale our product, and bring real benefit-risk clarity to both the pharma industry and patients. We’re thrilled to be backed by The Moon Venture whose team of founders turned investors bring unparalleled access to global entrepreneurs and healthtech networks, and Pléiade Venture, who are known for helping startups scale to profitability and long-term success.
According to the research, the global benefit-risk evaluation market is valued at $13 billion annually. As AI adoption in healthcare accelerates, experts predict that 80 per cent of pharmaceutical companies will rely on AI solutions for benefit-risk evaluation by 2026. ArcaScience is already seeing traction from this shift, working with global pharma leaders and top research institutions.
ArcaScience is solving a critical need in the pharmaceutical industry with a groundbreaking technological approach,
said the team at The Moon Venture.
We’ve seen remarkable market traction to date, and we believe they are ideally positioned to have a major impact in the pharma and patient care industries. This investment aligns with our strategy of supporting companies that are transforming entire industries through AI.
ArcaScience already counts 10 pharma clients, including Sanofi, AstraZeneca, GSK, Takeda, ICON, and the Paris Brain Institute. The company is also a member of a newly formed pan-European consortium looking at ways to combat pediatric brain cancer with AI. The consortium was created by Sanofi and Imagine for Margo and also includes the Paris Brain Institute, the Institut Gustave Roussy, the Medical University of Vienna, as well as major pharma companies such as AstraZeneca, Roche, Merck, and some of the brightest institutions and companies in the world.
ArcaScience’s platform has been used by over 70,000 patients in the area of chronic skin diseases and is being adopted by clinical operations and pharmacovigilance leaders to derisk clinical trials and optimise drug development.
The funds will fuel US and UK expansion, the launch of ArcaScience’s first patient-facing solution focused on pediatric brain cancer and dermatological diseases, and the growth of its team to accelerate the translation of its AI into measurable clinical impact.
Would you like to write the first comment?
Login to post comments